Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Phase I/II trial of Evomela for ASCT in myeloma w/ schedule optimization and matched comparison w/ MEL200 finds higher MEL AUC was associated with MRD‑negative sCR/CR and suggests longer PFS using propensity‑matching approach.”
Title: Phase I/II Trial of Evomela for Autologous Transplant in Myeloma: Schedule Optimization and Matched Comparison with MEL200
Authors: Qaiser Bashir, Peter F. Thall, Jitesh Kawedia, Xun Xu, Cristina G. Knape, Ruby Delgado, Yago Nieto, Neeraj Y. Saini, Yosra M. Aljawai, Samer A. Srour, Jeremy L. Ramdial, Chitra Hosing, Uday R. Popat, Betul Oran, Partow Kebriaei, Sairah Ahmed, Oren Pasvolsky, Krina K. Patel, Sheeba K. Thomas, Mahmoud R. Gaballa, Jing Christine Ye, Robert Z. Orlowski, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash
You can read the Full Article on Blood Advances.
You can find other articles featuring Robert Orlowski on OncoDaily.
